{"id":"acetazolamide-first-then-furosemide","safety":{"commonSideEffects":[{"rate":"10-20%","effect":"Numbness and tingling"},{"rate":"5-10%","effect":"Nausea"},{"rate":"5-10%","effect":"Drowsiness"}]},"_chembl":{"chemblId":"CHEMBL20","moleculeType":"Small molecule","molecularWeight":"222.25"},"_dailymed":null,"mechanism":{"_ai_source":"featherless-qwen","explanation":"By inhibiting carbonic anhydrase, acetazolamide decreases the reabsorption of bicarbonate in the renal tubules, leading to increased excretion of bicarbonate, sodium, and water, which can help reduce intraocular pressure and treat glaucoma or edema.","oneSentence":"Acetazolamide inhibits carbonic anhydrase, reducing the formation of bicarbonate ions and increasing urinary excretion of sodium, potassium, and water.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T04:52:22.641Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Glaucoma"},{"name":"Edema"},{"name":"Seizures"}]},"trialDetails":[{"nctId":"NCT06092437","phase":"NA","title":"Investigating a Tailored Diuretic Algorithm in Acute Heart Failure Patients","status":"RECRUITING","sponsor":"Zuyderland Medisch Centrum","startDate":"2023-02-27","conditions":"Heart Failure Acute","enrollment":466},{"nctId":"NCT06535529","phase":"PHASE3","title":"Acetazolamide Versus Dapagliflozin in Acute Decompensated Heart Failure Patients","status":"RECRUITING","sponsor":"Helwan University","startDate":"2024-08-24","conditions":"Acute Decompensated Heart Failure","enrollment":60},{"nctId":"NCT01146288","phase":"NA","title":"Effect of Acetazolamide and Furosemide on Obesity-induced Glomerular Hyperfiltration","status":"COMPLETED","sponsor":"Rabin Medical Center","startDate":"2010-07","conditions":"Obesity-induced Hyperfiltration","enrollment":13}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":30,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_1","status":"active","brandName":"Acetazolamide first, then Furosemide","genericName":"Acetazolamide first, then Furosemide","companyName":"Rabin Medical Center","companyId":"rabin-medical-center","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Acetazolamide inhibits carbonic anhydrase, reducing the formation of bicarbonate ions and increasing urinary excretion of sodium, potassium, and water. Used for Glaucoma, Edema, Seizures.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}